EA201892583A1 - Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора - Google Patents

Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора

Info

Publication number
EA201892583A1
EA201892583A1 EA201892583A EA201892583A EA201892583A1 EA 201892583 A1 EA201892583 A1 EA 201892583A1 EA 201892583 A EA201892583 A EA 201892583A EA 201892583 A EA201892583 A EA 201892583A EA 201892583 A1 EA201892583 A1 EA 201892583A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
combination
antagonist
pure antagonists
nmda
Prior art date
Application number
EA201892583A
Other languages
English (en)
Other versions
EA036301B1 (ru
Inventor
Рамакришна Нироджи
Анил Карбхари Схинде
Прадип Джаяраджан
Гопинадх Бхирапунени
Рамасастри Камбхампати
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA201892583A1 publication Critical patent/EA201892583A1/ru
Publication of EA036301B1 publication Critical patent/EA036301B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение относится к чистому антагонисту 5-HTрецептора или его фармацевтически приемлемой соли(солям) в комбинации с или в дополнение к антагонисту NMDA рецептора и их применению при лечении когнитивных расстройств. Изобретение также относится к фармацевтической композиции, содержащей указанную комбинацию.
EA201892583A 2016-05-18 2016-08-03 Комбинация высокоселективных антагонистов 5-ht6 рецептора с антагонистом nmda рецептора EA036301B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641017203 2016-05-18
PCT/IB2016/054674 WO2017199072A1 (en) 2016-05-18 2016-08-03 Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist

Publications (2)

Publication Number Publication Date
EA201892583A1 true EA201892583A1 (ru) 2019-04-30
EA036301B1 EA036301B1 (ru) 2020-10-23

Family

ID=56940099

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892583A EA036301B1 (ru) 2016-05-18 2016-08-03 Комбинация высокоселективных антагонистов 5-ht6 рецептора с антагонистом nmda рецептора

Country Status (19)

Country Link
US (1) US11116764B2 (ru)
EP (1) EP3458040B1 (ru)
JP (1) JP6606298B2 (ru)
KR (1) KR102023748B1 (ru)
CN (1) CN109069449A (ru)
AU (1) AU2016407428B2 (ru)
BR (1) BR112018073396A2 (ru)
CA (1) CA3023828C (ru)
DK (1) DK3458040T3 (ru)
EA (1) EA036301B1 (ru)
HK (1) HK1258023A1 (ru)
HR (1) HRP20210640T1 (ru)
HU (1) HUE055083T2 (ru)
IL (1) IL262816B (ru)
MX (1) MX2018013969A (ru)
NZ (1) NZ747778A (ru)
SG (1) SG11201809725TA (ru)
WO (1) WO2017199072A1 (ru)
ZA (1) ZA201807311B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210338661A1 (en) * 2017-07-03 2021-11-04 Suven Life Sciences Limited New uses of a pure 5-ht 6 receptor antagonist
US20220409614A1 (en) * 2019-12-02 2022-12-29 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
KR20220110518A (ko) 2019-12-02 2022-08-08 수벤 라이프 사이언시스 리미티드 치매 환자의 행동 및 심리적 증상 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237599B2 (en) * 2002-11-28 2009-06-18 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
KR101808792B1 (ko) 2013-12-02 2017-12-13 수벤 라이프 사이언시스 리미티드 1-[(2-브로모페닐)술포닐]-5-메톡시-3-[(4-메틸-1-피페라지닐)메틸]-1h-인돌 디메실레이트 모노히드레이트의 대규모 생산 방법

Also Published As

Publication number Publication date
CN109069449A (zh) 2018-12-21
JP6606298B2 (ja) 2019-11-13
NZ747778A (en) 2020-03-27
HRP20210640T1 (hr) 2021-06-25
AU2016407428A1 (en) 2018-11-29
ZA201807311B (en) 2020-01-29
AU2016407428B2 (en) 2019-11-21
JP2019516696A (ja) 2019-06-20
EP3458040A1 (en) 2019-03-27
EA036301B1 (ru) 2020-10-23
WO2017199072A1 (en) 2017-11-23
IL262816B (en) 2020-05-31
DK3458040T3 (da) 2021-05-03
CA3023828C (en) 2019-08-27
BR112018073396A2 (pt) 2019-03-19
EP3458040B1 (en) 2021-01-27
KR102023748B1 (ko) 2019-09-20
MX2018013969A (es) 2019-03-21
US20190175586A1 (en) 2019-06-13
CA3023828A1 (en) 2017-11-23
KR20180136566A (ko) 2018-12-24
SG11201809725TA (en) 2018-12-28
HUE055083T2 (hu) 2021-10-28
US11116764B2 (en) 2021-09-14
IL262816A (en) 2018-12-31
HK1258023A1 (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
MY187047A (en) Selective pyy compounds and uses thereof
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
NZ737399A (en) Ccr2 modulators
CL2015001529A1 (es) Compuestos derivados de indol carboxamida, antagonistas del receptor p2x7; composicion farmaceutica y su uso para la prevencion o tratamiento de enfermedades neurodegenerativas y neuroinflamatorias, enfermedades oseas y articulares, enfermedades cardiovaculares, entre otras.
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
CY1123013T1 (el) Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
BR112017024852A2 (pt) antagonistas de receptor nk-1/nk-3 duplo para o tratamento de doenças dependentes de hormônio sexual
EA201691160A1 (ru) Антагонисты s1p3
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
SA519410097B1 (ar) P2x7 مشتقات رباعي هيدروكوينولين كمعارضات مستقبل
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
PH12017501736A1 (en) Indole derivatives
MX2017017155A (es) Antagonistas del receptor de tromboxano en erea/asma.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция